BILTHOVEN, Netherlands — Officials with the Swiss/Dutch biosurgery firm IsoTis SA announced the CE mark approval and commercial launch of OsSatura, a synthetic bone substitute that its developers say ...
Six years after FDA approval of the first bone growth factor, a bone morphogenetic protein, researchers and clinicians still seek a better understanding of these powerful substances, their uses and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback